siltuximab (Sylvant)
Jump to navigation
Jump to search
Indications
- treatment of Castleman's disease
Contraindications
Mechanism of action
- anti-IL-6 chimeric human-mouse monoclonal antibody
More general terms
References
- ↑ American Cancer Society. April 29, 2014 FDA Approves Sylvant (Siltuximab) for Castleman Disease http://www.cancer.org/cancer/news/fda-approves-sylvant-siltuximab-for-castleman-disease
- ↑ Wikipedia: Siltuximab http://en.wikipedia.org/wiki/Siltuximab
- ↑ Chustecka Z Medscape: April 24, 2014 Siltuximab: First-Ever Drug for Castleman's Disease http://www.medscape.com/viewarticle/824072